A federal judge refused to allow drug compounders to keep making copycats of Novo Nordisk A/S’s weight loss drug while a lawsuit plays out over the FDA’s decision to determine that the drug is no longer in shortage.

Novo Nordisk, the Danish maker of Ozempic and Wegovy, announced Tuesday that it has asked the Food and Drug Administration to approve an oral version of its anti-obesity medication, moving ahead in the race between drugmakers to offer a weight loss pill.

Novo Nordisk's (NVO) stock price dropped following Eli Lilly's announcement of positive Phase 3 trial results for its oral weight loss drug orforglipron—that helped patients shed weight and control blood sugar,